KELLY STEVENSON: Open Payments
NPI 1154634244 · KEARNEY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,114 in 60 payments from 15 companies in 2025. Trend: 2023 $485 · 2024 $474 · 2025 $1,114
Food & beverage: $1,114
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $334 |
| AstraZeneca Pharmaceuticals LP | 5 | $245 |
| Saluda Medical Americas, Inc. | 6 | $98 |
| Astellas Pharma US Inc | 2 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Novo Nordisk Inc | 3 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| PFIZER INC. | 2 | $39 |
| Abbott Laboratories | 2 | $36 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
Products named: VRAYLAR, FARXIGA, QULIPTA, Evoke, BREZTRI, Veozah, REXULTI, CAPLYTA.
Industry payments across NE — which companies pay providers there.
